Study of Remibrutinib for chronic hives not helped by antihistamines
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had chronic hives for at least 4 to 6 months, depending on your type
- Your hives are not well controlled with antihistamines
- You are willing to attend all study visits and procedures
- You do not have other skin diseases that cause itching or hives
- You are not pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with severe hives (chronic urticaria) that have not improved with the usual dose of the medicine omalizumab. It aims to better understand these cases and how they are managed, which may help improve future care.
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
Hear when a new Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.